Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in LBD therapeutics.
  • There will be more than 1.1 million diagnosed prevalent cases of LBD in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast.
  • Currently, there are three marketed products for the treatment of LBD.
  • R&D activity within the LBD space is negligible, with no pipeline products in late-stage clinical development.
  • Commercial sponsors dominate clinical trial development in LBD, with the US and the UK emerging as the key countries for conducting trials in this disease space.
  • Deals involving partnerships were the most common type of deals globally involving companies developing LBD assets.
Scope

GlobalData’s LBD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the LBD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global LBD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Key Findings
  • Disease Overview
  • Epidemiology Overview
    • Epidemiology Overview: Diagnosed Prevalent Cases of LBD in 2023 and 2028
  • Treatment Overview
    • Treatment Guidelines
  • Marketed Drugs Assessment
    • Marketed Drugs – Leading Marketed Drugs in LBD
    • Marketed Drugs – Overview by Mechanism of Action
    • Marketed Drug Profile: Sumitomo Pharma’s Trerief
    • Marketed Drug Profile: Eisai’s Aricept
    • Marketed Drug Profile: Instituto Vital’s Rivastigmine Hemitartrate
  • Pricing and Reimbursement Assessment
    • Marketed Drugs – Manufacturer Price for Oral Formulations for LBD
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview – Mid-to-Late-Stage Pipeline Drugs in LBD
    • Pipeline Drugs – Overview by Development Stage
    • Pipeline Drugs – Overview by Mechanism of Action
    • Pipeline Drugs – Overview by Route of Administration
    • Pipeline Drugs – Overview by Molecule Type
    • Pipeline Drugs – PTSRs and LoAs in CNS
  • Clinical Trials Assessment
    • Clinical Trials in LBD – Historical Overview
    • Clinical Trials in LBD – Overview by Phase
    • Clinical Trials in LBD – Overview by Status
    • Clinical Trials in LBD – Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in LBD – Trials with a Virtual Component
    • Clinical Trials in LBD – Geographic Overview
    • Clinical Trials in LBD – Single-Country and Multinational Trials by Region
    • Clinical Trials in LBD – Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in LBD – Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in LBD – Overview by Endpoint Status
    • Clinical Trials in LBD – Overview by Race
    • Clinical Trials in LBD – Enrollment Data
    • Clinical Trials in LBD – Overview of Sites by Geography
    • Clinical Trials in LBD – Top 20 Countries for Trial Sites
    • Clinical Trials in LBD – Top 20 Sites Globally
    • Clinical Trials – Feasibility Analysis: Geography Overview
    • Clinical Trials – Feasibility Analysis: Benchmark Models for LBD
  • Deals Landscape
    • Deals Landscape – Mergers, Acquisitions, and Strategic Alliances in LBD by Region
    • Deals Landscape – Recent Mergers, Acquisitions, and Strategic Alliances in LBD
  • Commercial Assessment
    • Commercial Assessment – Key Market Players in LBD
  • Future Market Catalysts
    • Future Market Catalysts – Upcoming Market Catalysts in LBD
  • Appendix
    • Methodology
    • Methodology – Sales Forecasts
    • Methodology – Pricing and Reimbursement
    • Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings